{"cluster": 36, "subcluster": 18, "abstract_summ": "IL\u20101 blockage with anakinra has been shown to be safe and is associated with clinical improvement in patients with hyperinflammatory COVID\u201019 (Cavalli, et al 2020).Sars-CoV-2 complications include pneumonia and acute respiratory distress syndrome (ARDS), which require intensive care unit admission.A subgroup of patients with COVID\u201019 pneumonia develop a hyperinflammatory syndrome which has a similar cytokine release profile to secondary haemophagocytic lymphohistiocytosis (HLH) (Huang, et al 2020).Severe cases of coronavirus disease 2019 (COVID-19) are usually accompanied by an exuberant immune response comparable to cytokine release syndrome (CRS), with markedly elevated serum levels of proinflammatory cytokines which are thought to be a major drivers of morbidity and mortality for these patients (Huang, et al 2020).Several drugs with anti-inflammatory properties (tocilizumab, siltuximab, sarilumab, anakinra, among others) have been suggested as adjuncts to supportive care in the management of COVID-19, and several clinical trials are underway (NCT04315298, NCT04317092, NCT04306705).Particularly, since pneumonia and ARDS are associated with a cytokine storm, drugs belonging to therapeutic classes as anti-IL-6, anti-TNF, and JAK inhibitors are currently studied.", "title_summ": "[Rationales for using JAK 1/2 inhibitors in severely afflicted patients with COVID-19 pneumonia].IL\u20101 blockade with anakinra in acute leukaemia patients with severe COVID\u201019 pneumonia appears safe and may result in clinical improvementExploring pharmacological approaches for managing cytokine storm associated with pneumonia and acute respiratory distress syndrome in COVID-19 patientsProtective role of Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukaemia and COVID\u201019", "title_abstract_phrases": "IL\u20101 blockage with anakinra has been shown to be safe and is associated with clinical improvement in patients with hyperinflammatory COVID\u201019 (Cavalli, et al 2020).Exploring pharmacological approaches for managing cytokine storm associated with pneumonia and acute respiratory distress syndrome in COVID-19 patientsSars-CoV-2 complications include pneumonia and acute respiratory distress syndrome (ARDS), which require intensive care unit admission.Protective role of Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukaemia and COVID\u201019Severe cases of coronavirus disease 2019 (COVID-19) are usually accompanied by an exuberant immune response comparable to cytokine release syndrome (CRS), with markedly elevated serum levels of proinflammatory cytokines which are thought to be a major drivers of morbidity and mortality for these patients (Huang, et al 2020).A subgroup of patients with COVID\u201019 pneumonia develop a hyperinflammatory syndrome which has a similar cytokine release profile to secondary haemophagocytic lymphohistiocytosis (HLH) (Huang, et al 2020).IL\u20101 blockade with anakinra in acute leukaemia patients with severe COVID\u201019 pneumonia appears safe and may result in clinical improvementAs of 17th May, 2020 the number of patients infected by coronavirus disease 2019 (COVID\u201019) worldwide has exceeded 4.5 million (WHO 2020).Several drugs with anti-inflammatory properties (tocilizumab, siltuximab, sarilumab, anakinra, among others) have been suggested as adjuncts to supportive care in the management of COVID-19, and several clinical trials are underway (NCT04315298, NCT04317092, NCT04306705)."}